Welcome to our dedicated page for Cryo-Cell Intl SEC filings (Ticker: CCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cryo-Cell International, Inc. (CCEL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-generated summaries to help interpret complex documents. As a NYSE American–listed company engaged in cellular processing, cryogenic storage, and cord blood banking, Cryo-Cell uses its SEC filings to report on financial performance, governance, financing arrangements, and material events.
Investors can review annual reports on Form 10-K for a comprehensive discussion of the company’s business, including its private and public cord blood banking operations, the role of PrepaCyte-CB processing technology, the ExtraVault biostorage offering, and the license agreement with Duke University. Quarterly reports on Form 10-Q provide interim financial data, segment revenue details such as processing and storage fees, public banking revenue, and product revenue, as well as updates on research and development spending and other operating items.
Current reports on Form 8-K document specific material events. Recent examples include disclosures about decisions to declare or not declare quarterly cash dividends, amendments to the company’s Credit Agreement with Susser Bank, and the setting of the annual meeting date and record date. These filings also describe changes to revolving credit commitments, maturity dates, and the addition of subsidiaries such as Celle Corp. as guarantors, which are relevant for understanding Cryo-Cell’s capital structure and liquidity.
The definitive proxy statement on Schedule DEF 14A outlines board composition, proposals for director elections, auditor ratification, and advisory votes on executive compensation, as well as stockholder voting procedures. Form 4 and related insider transaction reports, when available, can be used to track trading activity by directors and officers.
Stock Titan’s AI tools summarize key points from 10-K, 10-Q, 8-K, DEF 14A, and other filings, helping users quickly identify disclosures on dividends, credit facilities, governance matters, and strategic initiatives without reading every page of the original documents.
Camac Fund and related entities disclosed a 5.3% stake in Cryo-Cell International, Inc. common stock on a Schedule 13D. They report beneficial ownership of 430,900 shares, acquired for approximately $1,354,672, based on 8,055,150 shares outstanding as stated in Cryo-Cell’s Form 10-K for the period ended November 30, 2026.
The position was purchased with working capital and is held through Camac Fund, with Camac Partners, Camac Capital and Eric Shahinian sharing voting and dispositive power. The investors state they believed the shares were undervalued and may increase or decrease their holdings or use hedging strategies over time.
The group describes itself as active, indicating plans to periodically review the investment and potentially engage with Cryo-Cell’s management, Board, other stockholders and third parties on topics such as Board composition and corporate governance, spending levels, monetization of company assets and return of capital to shareholders.
Cryo-Cell International, Inc. has received a notice from NYSE American that it is not in compliance with continued listing standards under Section 1003(a) of the NYSE American Company Guide. The exchange cited a stockholders’ deficit as of November 30, 2025 and net losses in two of the three most recent fiscal years.
The company’s common stock will continue trading on NYSE American under the symbol CCEL while it prepares and submits a compliance plan, which it intends to file by April 8, 2026. If the plan is not accepted or compliance is not regained within any allowed period, NYSE American may begin delisting proceedings.
Cryo-Cell International, Inc. provides cord blood and cord tissue processing and storage, manufactures the PrepaCyte CB processing system, and operates both private and public cord blood banking, including units listed through the National Marrow Donor Program.
The company highlights its cGMP/cGTP-compliant facilities, AABB and FACT accreditations, over 250,000 specimens stored with global affiliates, and a new Durham, North Carolina facility that also supports the ExtraVault third‑party cold storage service for biopharma customers.
A central theme is the now-contested Duke License Agreement. Cryo-Cell alleges Duke fraudulently induced and then breached the agreement, has filed an arbitration demand claiming damages it believes exceed $100 million, and has recorded a full impairment of the related asset. Duke has issued a notice of termination effective May 17, 2025 and asserted counterclaims for breach and indemnity, with a final arbitration hearing scheduled for April 2026.
Until this dispute is resolved, expansion into infusion clinics and biopharmaceutical manufacturing, the opening of the Cryo-Cell Institute for Cellular Therapies, and the proposed spin-off of its Celle Corp. subsidiary are all on hold, and the company cautions that the arbitration outcome could materially affect its business and financial position.
Cryo-Cell International Inc. director, Chairman and Co-CEO David Portnoy reported updated holdings and new equity awards. On January 7, 2026, he was granted two direct stock option awards: one for 50,000 shares and another for 150,000 shares of common stock, both with an exercise price of $3.89 per share and expirations in 2031.
The 50,000 options vest in three equal parts: upon grant, on January 7, 2027, and on January 7, 2028. The 150,000 options, granted under the Cryo-Cell 2022 Stock Incentive Plan, are split into three equal tranches that each require both time-based service and stock-price performance hurdles of $6, $8, and $10 per share, each measured over 20 consecutive trading days after the first, second, and third anniversaries of grant.
Cryo-Cell International's Chief Information Officer, Oleg Mikulinsky, reported new equity awards and existing holdings. On January 7, 2026, he received two grants of stock options on the company’s common stock at an exercise price of $3.54 per share, one for 10,000 options that vest in thirds on January 7, 2026, 2027 and 2028, and another for 20,000 options granted under the Cryo-Cell 2022 Stock Incentive Plan with three tranches tied to both time and stock-price performance hurdles at $6, $8, and $10 per share over specified 20-day periods. He also reports direct ownership of 104,349 common shares and several prior option awards with varying exercise prices and vesting schedules.
Cryo-Cell International Co-CEO Mark Portnoy reported new stock option grants and updated his holdings in company securities. On January 7, 2026, he was granted a stock option for 50,000 shares of common stock at an exercise price of $3.89 per share, expiring on January 7, 2031. This grant, made under the Cryo-Cell 2022 Stock Incentive Plan, is split into three equal tranches that each require both time-based vesting and stock price hurdles of $6, $8, and $10 per share over 20 consecutive trading days.
Portnoy also received a separate stock option for 25,000 shares at an exercise price of $3.89 per share, expiring January 7, 2031, which vests one-third upon issuance, one-third on January 7, 2027, and one-third on January 7, 2028. Following these grants, he reports 821,973 common shares held directly, 42,266 shares held indirectly via a 401(k), and 71,529 shares held indirectly by Capital Asset Fund #1 Limited Partnership, where he may be deemed a beneficial owner as general partner.
Cryo-Cell International disclosed new equity awards to its VP Finance and CFO, Jill M. Taymans. On January 7, 2026, she received two stock option grants at an exercise price of $3.54 per share. One grant covers 10,000 options that vest one-third on the grant date, one-third on January 7, 2027, and one-third on January 7, 2028. The second grant covers 20,000 options under the Cryo-Cell 2022 Stock Incentive Plan, split into three equal tranches that each require both time-based vesting and the stock reaching average closing prices of at least $6, $8, and $10 per share over 20 consecutive trading days, tied to the first, second, and third anniversaries of the grant. Taymans also reports 45,396 shares of common stock owned directly and multiple prior option awards with expirations ranging from 2026 to 2031.
Cryo-Cell International (CCEL) Chairman and Co-CEO David Portnoy filed a Form 4 reporting open-market purchases of common stock. On 11/20/2025, he acquired 289 shares at $4.00 per share, and on 11/21/2025 he acquired 800 shares at $4.04 and additional shares at $4.09 and $4.10, including purchases held as custodian for his son. Following these transactions, his directly held common stock increased to 847,629 shares, with additional indirect holdings through family accounts and various entities.
The filing also lists several stock option grants over prior years with exercise prices between $4.30 and $12.27, covering amounts such as 280,000 and 50,000 underlying shares, and expirations from 2027 to 2030. Some options vest over time on specified future dates, while one grant vests in full if the company’s share price reaches $25.00 during its seven-year term.
Cryo-Cell International (CCEL) director, 10% owner, and Chairman/Co-CEO David Portnoy reported open-market purchases of the company’s common stock. He bought 1,429 shares at $4.00 on 11/17/2025, 640 shares at $4.09 on 11/18/2025, and 1,921 shares at a weighted average price of $4.08 on 11/19/2025.
Following these transactions, he directly beneficially owns 846,540 common shares and also reports additional indirect holdings through various entities and family accounts. He further holds several stock option awards, including grants exercisable at prices ranging from $4.30 to $12.27 per share with expirations between 2027 and 2030 and vesting schedules tied to time and, in one case, the stock reaching $25.00 per share.
Cryo-Cell International (CCEL) insider David I. Portnoy (Director, 10% Owner, Chairman, Co-CEO) reported open-market purchases of common stock. He acquired 1,026 shares at $4.18 on 11/10/2025, 2,474 shares at a weighted average price of $4.13 on 11/11/2025, and 2,040 shares at a weighted average price of $4.12 on 11/12/2025. Following these trades, his direct beneficial ownership stands at 842,550 shares.
He also reports derivative holdings, including 280,000 stock options at $12.27 expiring 12/22/2028, which vest immediately if the stock reaches $25 during the seven-year term.